Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19
The Pharma Data
OCTOBER 27, 2020
MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage. During the clinical development stage, Molecular Partners will provide clinical supply.
Let's personalize your content